RT Journal Article
SR Electronic
T1 Core warming of coronavirus disease 2019 (COVID-19) patients undergoing mechanical ventilation - a pilot study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.12.23287815
DO 10.1101/2023.04.12.23287815
A1 Bonfanti, Nathaniel P
A1 Mohr, Nicholas M
A1 Willms, David C
A1 Bedimo, Roger J
A1 Gundert, Emily
A1 Goff, Kristina L
A1 Kulstad, Erik B
A1 Drewry, Anne M
YR 2023
UL http://medrxiv.org/content/early/2023/04/17/2023.04.12.23287815.abstract
AB Fever is a recognized protective factor in patients with sepsis, and growing data suggest beneficial effects on outcomes in sepsis with elevated temperature, with a recent pilot randomized controlled trial showing lower mortality by warming afebrile sepsis patients in the intensive care unit. The objective of this prospective single-site randomized controlled trial was to determine if core warming improves respiratory physiology of mechanically ventilated patients with COVID-19, allowing earlier weaning from ventilation, and greater overall survival. A total of 19 patients with mean age of 60.5 (±12.5) years, 37% female, mean weight 95.1 (±18.6) kg, and mean BMI 34.5 (±5.9) kg/m2 with COVID-19 requiring mechanical ventilation were enrolled from September 2020 through February 2022. Patients were randomized 1:1 to standard-of-care or to receive core warming for 72 hours via an esophageal heat exchanger commonly utilized in critical care and surgical patients. The maximum target temperature was 39.8 °C. A total of 10 patients received usual care and 9 patients received esophageal core warming. After 72 hours of warming, PaO2/FiO2 ratios were 197 (±32) and 134 (±13.4), Cycle Thresholds were 30.8 (±6.4) and 31.4 (±3.2), ICU mortality was 40% and 44%, 30-day mortality was 30% and 22%, and mean 30-day ventilator-free days were 11.9 (±12.6) and 6.8 (±10.2) for standard-of-care and warmed patients, respectively (p=NS). This pilot study suggests that core warming of patients with COVID-19 undergoing mechanical ventilation is feasible and appears safe. Optimizing time to achieve febrile-range temperature may require a multimodal temperature management strategy to further evaluate effects on outcome.Competing Interest StatementDr. Willms, disclosures limited to: i.Speaker Bureau, La Jolla Pharmaceutical Company ii.Board of Directors & Investor, Octet Medical, Inc iii.Investor and Medical Advisor, InVent Respiratory and Connected Rock Ventures Dr. Bedimo, disclosures limited to: i.Research support from Merck & Co. ii.Scientific advisory board for Merck & Co., Shionogi, Gilead, and Theratechnologies Dr. Kulstad, disclosure limited to equity and employment in Attune Medical Clinical TrialNCT04494867Funding StatementThis did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Sharp Memorial Hospital gave ethical approval for this work. IRB # 2007901; approved August 17, 2020I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.